Though often overlooked or made by default, decisions about the structure and timing of a competitive deal process can have a significant impact on the ultimate value realized by the sell-side company.
CATEGORIES News Events Publications ARCHIVE Locust Walk is recruiting at your Campus! Locust Walk recruits undergraduate and graduate level candidates
CATEGORIES News Events Publications ARCHIVE Locust Walk and Halloran Consulting collaboration during GTC Bio CNS Disease Summit Conference in Boston
CATEGORIES News Events Publications ARCHIVE What is the regulatory STATE of stem cells? Stem cells seem to be everywhere. We
CATEGORIES News Events Publications ARCHIVE What is the Point of Point of Care? After stops and starts, successes and disappointments,
Over the past years, I have had the fortune of participating in negotiations and ultimate deals between Western and Japanese biopharmaceutical companies.
With the new school year just around the corner here in Boston (and already underway in other parts of the country), transactions involving academic
CATEGORIES News Events Publications ARCHIVE Triangulation: The key to valuing early stage medical technology companies At different stages of development,
A few months ago, I posted a related article about deal timing titled ‘Maintaining Deal Momentum in the Summer Months’. Now it is early August, and we are deep in the summer slowdown.
As an early advocate for the importance of the family office in the biotech financing landscape, I have learned from recent experience what many entrepreneurs already know. Raising money from family offices is hard.